Login to Your Account

Clementia starts first global phase III trial in ultra-rare bone disorder

By Michael Fitzhugh
Staff Writer

Tuesday, December 12, 2017

Just four months out from its $128.2 million August IPO, Montreal-based Clementia Pharmaceuticals Inc. is moving palovarotene, its lead candidate, into a registrational phase III trial testing its ability to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone disorder.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription